Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) Bundle
Dive into a data-driven appraisal of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): with 2024 operating revenue of CNY 1.35 billion-a 20.82% year-over-year gain and a five-year CAGR of ~10.96%-and a 73.35% gross profit margin, the company shows standout top-line growth and cost control, while net income reached CNY 238 million in 2024 (up 5.15%) delivering a 17.6% net profit margin and EPS (TTM) of CNY 1.37; operational metrics include a 2024 operating margin of 10.24%, ROE of 8.38%, revenue per employee of CNY 876,932, and an operating cash flow (TTM) of CNY 334.74 million that produced free cash flow of CNY 254.57 million-backed by cash and equivalents of CNY 971 million and a net cash position of CNY 1.41 billion-while conservative leverage (total debt CNY 110 million, debt/equity 0.05), an interest coverage ratio of 49.23, current ratio 3.46 and quick ratio 3.05 drive an Altman Z-Score of 6.73; valuation shows investor optimism with trailing and forward P/Es of 41.44 and 35.45, P/B 3.35, EV/EBITDA 36.17 and market cap ≈ CNY 9.82 billion (as of 17 Dec 2025) amid a low beta of 0.16, even as investors weigh sector risks-regulatory pressure, generic competition, raw-material cost swings, IP and execution risks-and growth levers like oncology/cardiovascular focus, R&D investment, CDMO expansion and planned strategic deals such as the Shanghai Chaoyang stake.
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) Revenue Analysis
- Operating revenue (FY-ending Dec 2024): CNY 1.35 billion - a 20.82% increase from CNY 1.12 billion in 2023.
- Five‑year revenue CAGR: approximately 10.96%.
- Gross profit margin (2024): 73.35% - gross profit ≈ CNY 990.23 million.
- Revenue per employee: CNY 876,932 - implied workforce ≈ 1,539 employees.
- Revenue diversification: sales across oncology, cardiovascular and other therapeutic areas.
- Growth drivers: alignment with China's expanding biopharma market and rising healthcare demand.
| Year | Operating Revenue (CNY) | YoY Change |
|---|---|---|
| 2020 | 950,000,000 | - |
| 2021 | 1,030,000,000 | +8.42% |
| 2022 | 1,080,000,000 | +4.85% |
| 2023 | 1,120,000,000 | +3.70% |
| 2024 | 1,350,000,000 | +20.82% |
- Profitability snapshot: With a 73.35% gross margin in 2024, Chengdu Easton converts a high share of revenue to gross profit (≈CNY 990.23M), supporting R&D and SG&A investment.
- Operational efficiency: Revenue per employee (CNY 876,932) indicates above‑industry productivity for a mid‑cap biopharma focused on high‑value therapeutic segments.
- Revenue mix and resilience:
- Oncology: core high-margin revenue contributor.
- Cardiovascular: stable recurring sales supporting diversification.
- Other therapeutic areas: incremental sales reducing single-market concentration risk.
- Industry context: Revenue growth is consistent with broader Chinese biopharmaceutical expansion driven by aging population, policy support, and rising per‑capita healthcare spend.
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Profitability Metrics
Chengdu Easton Biopharmaceuticals reported solid profitability for fiscal year 2024, with year-over-year net income growth and margins that compare favorably within the biotechnology sector. Key headline figures include net income of CNY 238 million (up 5.15% from CNY 226 million in 2023), a net profit margin of approximately 17.6%, an operating margin of 10.24%, TTM EPS of CNY 1.37 and a P/E ratio of 41.77. Return on equity stands at 8.38%, reflecting reasonable returns on shareholders' capital relative to growth and reinvestment needs.- Net income (2024): CNY 238 million (+5.15% vs. 2023 CNY 226 million)
- Net profit margin (2024): ~17.6%
- Operating margin (2024): 10.24%
- TTM EPS: CNY 1.37
- Price-to-earnings (P/E): 41.77
- Return on equity (ROE): 8.38%
- Sector context: Biotechnology average P/E ≈ 35
| Metric | 2024 Value | 2023 / Context |
|---|---|---|
| Net Income | CNY 238 million | CNY 226 million (2023), +5.15% YoY |
| Net Profit Margin | 17.6% | High relative to many peers in biotech |
| Operating Margin | 10.24% | Indicates operational efficiency |
| EPS (TTM) | CNY 1.37 | Used to compute P/E |
| P/E Ratio | 41.77 | Biotech average ≈ 35 |
| ROE | 8.38% | Moderate return on equity |
- Profitability drivers: improved revenue mix and controlled operating expenses supported the 10.24% operating margin and 17.6% net margin.
- Valuation note: P/E of 41.77 is above the sector average (~35), implying higher growth expectations priced in by the market.
- Capital efficiency: ROE of 8.38% suggests room to enhance returns via margin expansion or more accretive capital deployment.
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Debt vs. Equity Structure
As of December 2024, Chengdu Easton Biopharmaceuticals presents a conservative capital structure characterized by very low leverage, a strong net cash position, and modest capital investment during the year.
| Metric | Value (CNY million) | Notes |
|---|---|---|
| Total debt | 110 | Short- and long-term borrowings combined |
| Shareholders' equity | 2,200 | Implied from debt-to-equity ratio (Debt / Equity = 0.05) |
| Debt-to-equity ratio | 0.05 | Indicates conservative leverage |
| Cash & cash equivalents | 971 | Provides liquidity and strategic flexibility |
| Net debt (Debt - Cash) | -861 | Net cash position |
| Interest coverage ratio | 49.23x | Strong ability to service interest expense |
| Capital expenditures (2024) | 117 | Measured investment in capacity/R&D-supporting assets |
- Low leverage (D/E = 0.05) limits financial risk and downside sensitivity to revenue shocks.
- Net cash of CNY 861 million (negative net debt) supports near-term R&D funding without external financing.
- Interest coverage of 49.23x provides a wide cushion for interest obligations, reducing refinancing risk.
- CapEx of CNY 117 million in 2024 shows measured reinvestment rather than aggressive expansion.
- Low debt is especially advantageous in biopharma where R&D and scale-up can demand large, uncertain capital outlays.
For investor context and ownership trends, see: Exploring Chengdu Easton Biopharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Liquidity and Solvency
Chengdu Easton Biopharmaceuticals presents a solid liquidity and solvency profile, underpinned by strong short-term ratios, significant operating cash generation, and a net cash balance that cushions against macro and sector-specific volatility. Key numeric indicators below quantify this strength and its implications for operations, R&D, and potential M&A or business development.
- Current ratio: 3.46 - more than three times short-term liabilities covered by current assets.
- Quick ratio: 3.05 - indicates immediate liquidity remains robust even excluding inventories.
- Operating cash flow (TTM): CNY 334.74 million.
- Capital expenditures (TTM): CNY 80.16 million.
- Free cash flow (TTM): CNY 254.57 million (Operating CF - CapEx).
- Net cash position: CNY 1.41 billion - net of debt, providing financial flexibility.
- Altman Z-Score: 6.73 - indicative of very low bankruptcy risk.
| Metric | Value | Remarks |
|---|---|---|
| Current Ratio | 3.46 | Strong short-term coverage |
| Quick Ratio | 3.05 | High immediate liquidity |
| Operating Cash Flow (TTM) | CNY 334.74 million | Healthy cash generation from operations |
| Capital Expenditures (TTM) | CNY 80.16 million | Moderate capex relative to cash flow |
| Free Cash Flow (TTM) | CNY 254.57 million | Available for dividends, R&D, or M&A |
| Net Cash | CNY 1.41 billion | Low leverage and sizable liquidity buffer |
| Altman Z-Score | 6.73 | Very low default probability |
- Compared with industry averages, Chengdu Easton's liquidity ratios are favorable, signaling above-peer resilience to short-term shocks.
- The free cash flow coverage (CNY 254.57M) comfortably funds ongoing R&D and strategic initiatives without eroding the cash buffer.
- Net cash of CNY 1.41B permits opportunistic business development or bolt-on acquisitions while maintaining a conservative balance sheet.
For investor context and shareholder activity related to the company, see: Exploring Chengdu Easton Biopharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Valuation Analysis
Chengdu Easton Biopharmaceuticals' current valuation profile signals a premium growth expectation from the market while showing lower downside volatility relative to broader indices. Core valuation metrics as of December 17, 2025 are presented below and contextualized against investor expectations and industry norms.
- Trailing P/E: 41.44 - implies investors have paid a high multiple for historically reported earnings.
- Forward P/E: 35.45 - reflects expected earnings growth; forward multiple is lower than trailing, indicating anticipated earnings improvement.
- P/B: 3.35 and P/TBV: 3.39 - market prices roughly 3.3x book and tangible book value, consistent with premium for biotech/biopharma intellectual property and pipeline value.
- EV/EBITDA: 36.17 - a notable premium versus typical corporate averages, consistent with growth-company valuations in the sector.
- Market capitalization: ~CNY 9.82 billion (as of 2025-12-17).
- Beta: 0.16 - indicates substantially lower volatility than the market, suggesting relative defensive behavior or limited correlation with market swings.
- Overall: valuation metrics are broadly in line with industry comparables, implying investor confidence in near-to-medium-term prospects.
| Metric | Value | Interpretation |
|---|---|---|
| Trailing P/E | 41.44 | High multiple on historical earnings - growth priced in |
| Forward P/E | 35.45 | Lower than trailing P/E - market expects earnings acceleration |
| Price-to-Book (P/B) | 3.35 | Market values assets and intangibles at a premium |
| Price-to-Tangible Book (P/TBV) | 3.39 | Consistent premium after excluding intangible assets |
| EV / EBITDA | 36.17 | Elevated enterprise multiple signaling growth expectations |
| Market Capitalization | CNY 9.82 billion | Market size as of 2025-12-17 |
| Beta (1Y) | 0.16 | Low volatility relative to market |
Key valuation implications for investors:
- High P/E and EV/EBITDA suggest the market is pricing meaningful future revenue and margin expansion; downside risk if growth stalls.
- Strong P/B and P/TBV reflect value placed on pipeline, R&D and intangible assets typical in biopharma.
- Low beta may reduce portfolio volatility contribution, but liquidity and sector-specific risks remain.
- Comparative alignment with industry multiples supports the narrative of investor confidence.
For context on corporate strategy that may drive these valuation multiples, see: Mission Statement, Vision, & Core Values (2026) of Chengdu Easton Biopharmaceuticals Co., Ltd.
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Risk Factors
Chengdu Easton Biopharmaceuticals operates in a high-regulation, capital-intensive sector where operational, market and policy risks can materially affect financial health. Below are the principal risk vectors investors should weigh, with industry context and quantified sensitivities where relevant.
- Regulatory & pricing pressures: China's healthcare reforms and reimbursement negotiations (including NRDL adjustments) frequently compress prices for generics and selected biologics. China's total pharmaceutical market was approximately RMB 1.8-1.9 trillion in 2023, and reimbursement-driven price declines of 5-25% have been observed for impacted categories in prior rounds.
- Competition in generics: Reliance on generic drug manufacturing exposes the company to intense domestic consolidation and low-cost international entrants. Generic ASP (average selling price) erosion of 10-30% over a 2-3 year horizon is common in highly contested molecules.
- Raw material and input cost volatility: API and excipient price swings, driven by feedstock shortages or export controls, can change COGS materially. Industry reports show API price volatility ranging up to ±30% during supply shocks, which can reduce gross margins by several percentage points.
- Expansion & execution risk: Moving into new therapeutic areas (e.g., specialty biologics or high-barrier niches) requires successful R&D, regulatory approvals and manufacturing scale-up. Typical timelines can slip by 12-36 months, increasing development spend and delaying revenue recognition.
- Intellectual property exposure: Patent expirations, weak patent fences for generics, or litigation can remove exclusivity or impose damages. Loss of exclusivity on a mid-size product can cut related revenue by 50-100% within 12 months as generics enter.
- Macroeconomic & healthcare spending cycles: Economic slowdown or constrained public healthcare budgets can reduce demand growth. Scenario analysis often models top-line declines of 5-15% under severe fiscal tightening.
| Risk Category | Probability (Industry Estimate) | Potential Financial Impact | Typical Time Horizon |
|---|---|---|---|
| Regulatory / Pricing Reforms | High (60-80%) | Revenue decline 5-25%; margin compression 2-10 pp | 1-3 years |
| Generic Competition | High (70-90%) | Product-level revenue drop 30-100% post-entry | 0-2 years after generic launch |
| Input Cost Volatility | Medium (40-60%) | Gross margin swing ±2-8 pp | Months to 1 year |
| Expansion / Execution Risk | Medium-High (50-70%) | Increased OPEX/R&D by 10-50%; delayed revenues | 1-5 years |
| IP / Litigation | Medium (30-50%) | Royalty/payments or lost sales; one-time charges | 1-3 years |
| Macro / Healthcare Budget Cuts | Medium (30-50%) | Top-line decline 5-15% in stressed scenarios | 1-2 years |
- Balance sheet sensitivity: Given the above, investors should monitor working capital cycles (inventory days, receivable days), gross margin trends, and leverage. A 5-10% hit to revenue in a year combined with fixed-cost structure can swing EBITDA margins materially; stress tests for 10-20% revenue shocks are standard practice.
- Operational indicators to watch:
- R&D spend as % of revenue - a rising ratio may signal higher burn while pursuing new therapies.
- CPR (capacity utilization) and time-to-commercialize for new lines - key to judging expansion execution.
For historical and structural context on the firm, see: Chengdu Easton Biopharmaceuticals Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) - Growth Opportunities
Chengdu Easton Biopharmaceuticals (688513.SS) is positioned at the intersection of high-demand therapeutic areas and growing biopharma service markets in China and globally. Key vectors for future growth include therapeutic focus, geographic expansion, R&D pipeline buildout, strategic M&A, global partnerships, and CDMO service adoption.- Therapeutic focus: oncology and cardiovascular disease remain priority public-health and commercial categories in China, supporting sustained demand for new therapies and follow-on biologics.
- Geographic expansion: leveraging domestic scale to enter APAC, MENA, and select Western markets for revenue diversification.
- R&D-driven value creation: continued investment in proprietary assets to capture higher-margin product sales versus purely service-based revenue.
- M&A and minority investments: targeted transactions (e.g., planned stake in Shanghai Chaoyang) to broaden the product and technology portfolio quickly.
- Partnerships and licensing: co-development and out-licensing deals with global pharma to accelerate late-stage development and commercialization.
- CDMO and CDO service expansion: scaling contract manufacturing and development capabilities to capture predictable, recurring revenues.
| Metric | Estimate / Data | Sources / Notes |
|---|---|---|
| Ticker | 688513.SS | Shanghai Stock Exchange STAR Market |
| China oncology market size (2023) | ~RMB 250-300 billion | Market research estimates for oncology drug sales in China |
| China cardiovascular drug market (2023) | ~RMB 100-140 billion | Prescription and hospital channel sales estimates |
| China biologics/CDMO market (2023) | ~USD 6-10 billion (domestic portion); global CDMO ~USD 25-35 billion | Rapid domestic growth; global demand for outsourcing rising |
| Projected CDMO CAGR (China, 2024-2028) | ~12-18% annually | Reflects growing outsourcing by biotech/pharma |
| Typical biotech R&D intensity | 15-30% of revenue (industry range) | R&D-heavy firms invest a high share to sustain pipelines |
| Addressable patient population (oncology, China) | millions of new cases annually; high unmet need for new biologics | Large-and-growing incidence supports long-term demand |
- Oncology & cardiovascular focus: Aligns with the largest segments of therapeutic spend-successful late-stage assets could drive rapid top-line growth given China's large patient base and accelerating reimbursement reform.
- International expansion: Entering nearby markets (Southeast Asia, Middle East) can reduce concentration risk from domestic pricing/reimbursement pressures and capture higher-margin ex-China sales.
- R&D investment: Maintaining or increasing R&D intensity toward the 15-30% band is likely necessary to transition from CDMO/service revenue toward proprietary-product-driven profitability.
- M&A and minority stakes: The planned stake in Shanghai Chaoyang exemplifies inorganic growth to access complementary technologies, accelerate clinical-stage programs, and capture synergies.
- Partnership model: Co-development and licensing agreements with multinational pharma can accelerate registration in multiple territories while sharing development costs and risks.
- CDMO expansion: Diversifying into higher-capacity CDMO services (biologics fill/finish, sterile manufacturing) offers recurring revenue and utilization-levered margin expansion as global outsourcing demand grows.
- R&D spend as % of revenue - trend upward suggests pipeline commitment.
- Revenue mix - proportion of proprietary product sales vs CDMO/service revenue.
- Gross margin and adjusted EBITDA - margins will reflect shift toward product sales and higher-value CDMO services.
- Pipeline milestones - IND/CTA filings, pivotal trial starts, NDA/BLA submissions and approvals in China and abroad.
- M&A execution - size and strategic fit of acquisitions (e.g., Shanghai Chaoyang stake) and associated integration metrics.
- Partnerships/licensing deals - upfronts, milestones, and potential royalties that de-risk development costs.
- Manufacturing capacity utilization - utilization rates for CDMO lines and planned capex timelines.
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.